Construction and Evaluation of a Tuberculosis Multistage Vaccine Candidate Based on Recombinant Listeria ivanovii

LIU Ting, LIU Si-jing, ZHOU Yu-zhen, ZHANG Yun-wen, WANG Chuan

Abstract


To construct a recombinant Listeria ivanovii (LI) strain that expressed Mycobacterium tuberculosis (MTB) specific antigen protein as a novel multistage tuberculosis (TB) vaccine candidate, and evaluate the biosafety and immunogenicity in mouse model.  Methods  T cell epitopes of four genes related to different stages of MTB infection were fused in series to form an antigen gene, i.e. the multistage antigen gene (named msv). Then msv was inserted into the targeting plasmid that contained LI homologous sequences. Recombinant LI strain was obtained by transfecting LI with targeting plasmid and screening the recombinant LI strain that carried msv in the genome after series of homologous gene recombination processes. The growth rate of the recombinant LI strain in vitro was observed and the expression of target protein was verified by Western blot. The 50% lethal dose (LD50) of the recombinant strain to C57BL/6 mice was measured. Mice were intravenously inoculated with vaccine candidate in dose of 0.1×LD50.The serum alanine aminotransferase (ALT) levels, bacterial load in organs, and organ pathological sections before and 1, 2, 3, 5, 7, 14 d after vaccination were used to evaluate the safety of vaccine candidate strain. To analyze the immunogenicity of vaccine candidate strain, mice were intravenously inoculated with LI-msv, LI, and NS respectively. Nine days post immunization, the spleens were isolated under sterile conditions and splenocytes were collected and stimulated. Lyphocytes which secret specific cytokines, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2 were analyzed by flow cytometry.  Results  A recombinant strain named LI-msv which was capable of expressing the multistage TB antigen protein was successfully constructed. The LD50 value of LI-msv for C57BL/6 mice (i.v.) was 3.3×108 CFU. After intravenously immunized the mice, this strain mainly multiplied in the liver and spleen, and was cleared at 7 d post innoculation. Such infection process caused transient pathological damages of the liver and spleen. Results of flow cytometry showed specific IFN-γ+ CD4+ and IFN-γ+ CD8+ T lymphocytes were successfully induced in LI-msv immunized mice spleen lymphocytes. The frequency of IFN-γ positive CD4+ and CD8+ T cells was significantly higher than those of vector control group and NS control group (P<0.005). Additionally, the frequency of specific TNF-α+ CD4+ T cell in LI-msv immunized group was significantly higher than that of vector control (P<0.01) and NS control group (P<0.005), and TNF-α+ CD8+ T cell frequency obviously increased than NS control group (P<0.005).  Conclusions  A novel multistage TB vaccine candidate expressing TB multistage antigen based on LI was successfully constructed. This vaccine candidate is safe and can induce specific cellular immune response to some extent. It is promising to be further studied as a candidate vaccine against tuberculosis.

 

Keywords: Tuberculosis, Multistage tuberculosis vaccine, Listeria ivanovii, Safety, Immunogenicity

 

Full Text:

PDF


References


BUCHRIESER C， RUSNIOK C， GARRIDO P， et al. Complete genome sequence of the animal pathogen Listeria ivanovii, which provides insights into host specificities and evolution of the genus Listeria. J Bacteriol， 2011，193(23): 6787–6778.

LIN Q， ZHOU M， XU Z， et al. Construction of two Listeria ivanovii attenuated strains expressing Mycobacterium tuberculosis antigens for TB vaccine purposes. J Biotechnol，2015，196-197: 20–26.

ZHANG L， RU H W， CHEN F Z， et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol Ther，2016，24(2): 398–405.

LIU W， XU Y， YAN J， et al. Ag85B synergizes with ESAT-6 to induce efficient and long-term immunity of C57BL/6 mice primed with recombinant Bacille Calmette-Guerin. Exp Ther Med，2017，13(1): 208–214.

KARBALAEI ZADEH BABAKI M， SOLEIMANPOUR S， REZAEE S A. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microb Pathog，2017，112: 20–29.

AAGAARD C， HOANG T， DIETRICH J， et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. NatMed，2011，17: 189−194.

PERSONNE Y， BROWN A C， SCHUESSLER D L， et al. Mycobacterium tuberculosis ClpP proteases are co-transcribed but exhibit different substrate specificities. PLoS One， 2013， 8 (4): e60228[2019-07-17]. https://doi.org/10.1371/journal.pone.0060228. [

MCGILLIVRAY A， GOLDEN N A， KAUSHAL D. The Mycobacterium tuberculosis Clp gene regulator is required for in vitro reactivation from hypoxia-induced dormancy. J Biol Chem，2015，290(4): 2351–2367.

XIONG X， JIAO J， GREGORY A E， et al. Identification of Coxiella burnetii CD8+ T-cell epitopes and delivery by attenuated Listeria monocytogenes as a vaccine vector in a C57BL/6 mouse model. J Infect Dis，2017，215(10): 1580–1589.

JIA Y Y， TAN W J， DUAN F F， et al. A genetically modified attenuated Listeriavaccine expressing HPV16 E7 kill tumor cells in direct and antigen-specific manner. Front Cell Infect Microbiol， 2017， 7: 279[2019- 07-17]. https://doi.org/10.3389/fcimb.2017.00279.

SINHA S， KUO C Y， HO J K， et al. A suicidal strain of Listeria monocytogenes is effective as a DNA vaccine delivery system for oral administration. Vaccine，2017，35(38): 5115–5122.

VITIELLO M， EVANGELISTA M， DI LASCIO N， et al. Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene，2019，38(19): 3756–3762.


Refbacks

  • There are currently no refbacks.